secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001493152-22-033719
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NYSE American grants AgeX extension to May 17, 2023 to meet $4M equity minimum for continued listing
--------------------------------------------------------------------------------

- NYSE American accepted AgeX's revised compliance plan and extended deadline to May 17, 2023 for meeting $4M stockholders' equity minimum.
- If AgeX fails to comply by May 17, 2023 or fails to meet plan milestones, NYSE American will initiate delisting proceedings.
- AgeX intends to arrange for quotation on an electronic interdealer system (e.g., OTC) if delisted from NYSE American.
- The Exchange will periodically review AgeX's progress against plan milestones during the extension period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315222033719/0001493152-22-033719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315222033719/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-033719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer